Radiation ups event-free, not overall survival in ped Hodgkin's

May 31, 2012
Radiation ups event-Free, not overall survival in ped hodgkin's
For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy improves event-free survival, but has no significant impact on overall survival, in long-term follow-up, according to a study published online May 29 in the Journal of Clinical Oncology.

(HealthDay) -- For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy (IFRT) improves event-free survival (EFS), but has no significant impact on overall survival (OS), in long-term follow-up, according to a study published online May 29 in the Journal of Clinical Oncology.

Suzanne L. Wolden, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues presented long-term follow-up data from the Children's Cancer Group trial of 826 with Hodgkin's lymphoma. Participants were enrolled from 1995 to 1998, and 498 who achieved an initial complete response to were randomly allocated to IFRT or no further treatment. EFS and OS were assessed.

The researchers found that, for the entire cohort, the 10-year EFS and OS rates were 83.5 and 92.5 percent, respectively. For randomly-assigned patients in an as-treated analysis, the 10-year EFS was 91.2 percent for patients treated with IFRT, compared to 82.9 percent for patients with no further therapy (P = 0.004); the 10-year OS was 97.1 percent for IFRT and 95.9 percent for no further therapy (P = 0.50). Risk factors for inferior EFS included bulk disease, "B" symptoms, and nodular sclerosis histology.

"With a median follow-up of 7.7 years, IFRT produced a statistically significant improvement in EFS but no improvement in OS," the authors write. "Patient and disease characteristics and early response assessment will aid in deciding which patients are most likely to benefit from IFRT."

Explore further: High survival with surgery in low-risk neuroblastoma

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

High survival with surgery in low-risk neuroblastoma

April 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Recommended for you

Is there a link between telomere length and cancer?

March 23, 2017

Telomeres are regions of repetitive DNA at the end of human chromosomes, which protect the end of the chromosome from damage. Whilst shorter telomeres are hypothesized biological markers of older age and have been linked ...

Three-pronged approach is key to precision medicine

March 23, 2017

Combining genetic information from a patient's tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom ...

How the nervous system controls tumor growth

March 22, 2017

(Medical Xpress)—From the time it first comes online during development the nervous system begins to exact precise control over many biologic functions. In some cases, too much control. When it does, a little nerve-squelching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.